Total Payments
$169,544
2024 Payments
$31,547
Companies
28
Transactions
735
Medicare Patients
2,790
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$132,940 (78.4%)
Travel$19,164 (11.3%)
Food & Beverage$15,718 (9.3%)
Research$1,499 (0.9%)
Education$223.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $127,740 | 59 | 75.3% |
| Travel and Lodging | $19,164 | 86 | 11.3% |
| Food and Beverage | $15,718 | 565 | 9.3% |
| Honoraria | $5,200 | 1 | 3.1% |
| Unspecified | $1,499 | 13 | 0.9% |
| Education | $223.40 | 11 | 0.1% |
Payments by Type
General
$168,045
722 transactions
Research
$1,499
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $150,082 | 250 | $0 (2024) |
| LivaNova USA, Inc. | $6,979 | 18 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,829 | 55 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,600 | 56 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,499 | 13 | $0 (2019) |
| Lundbeck LLC | $1,244 | 101 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $976.13 | 68 | $0 (2024) |
| Neuronetics, Inc. | $963.66 | 17 | $0 (2024) |
| ITI, Inc. | $878.42 | 19 | $0 (2023) |
| ABBVIE INC. | $739.05 | 45 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,547 | 123 | Janssen Pharmaceuticals, Inc ($22,985) |
| 2023 | $66,255 | 197 | Janssen Pharmaceuticals, Inc ($63,287) |
| 2022 | $21,309 | 81 | Janssen Pharmaceuticals, Inc ($19,859) |
| 2021 | $12,527 | 88 | Janssen Pharmaceuticals, Inc ($11,435) |
| 2020 | $10,926 | 70 | Janssen Pharmaceuticals, Inc ($10,084) |
| 2019 | $24,968 | 111 | Janssen Pharmaceuticals, Inc ($22,431) |
| 2018 | $1,692 | 49 | Neuronetics, Inc. ($747.52) |
| 2017 | $320.91 | 16 | Neuronetics, Inc. ($91.85) |
All Payment Transactions
735 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.49 | General |
| 12/13/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: Neuroscience | ||||||
| 12/13/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.63 | General |
| Category: PSYCHIATRY | ||||||
| 11/22/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: CNS | ||||||
| 11/22/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $11.23 | General |
| Category: PSYCHIATRY | ||||||
| 11/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $7.26 | General |
| Category: PSYCHIATRY | ||||||
| 11/15/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $122.55 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.59 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.45 | General |
| Category: PSYCHIATRY | ||||||
| 10/30/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug), INVEGA SUSTENNA | Food and Beverage | In-kind items and services | $139.45 | General |
| Category: Neuroscience | ||||||
| 10/25/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: Neuroscience | ||||||
| 10/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $11.85 | General |
| Category: PSYCHIATRY | ||||||
| 10/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: PSYCHIATRY | ||||||
| 10/18/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.99 | General |
| Category: PSYCHIATRY | ||||||
| 10/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: PSYCHIATRY | ||||||
| 09/27/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: ANTI-ANXIETY | ||||||
| 09/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: NEUROSCIENCE | ||||||
| 09/20/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: PSYCHIATRY | ||||||
| 09/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: PSYCHIATRY | ||||||
| 09/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.46 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: ANTI-ANXIETY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,499 | 13 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 993 | 4,432 | $1.1M | $578,695 |
| 2022 | 13 | 672 | 3,086 | $559,341 | $285,705 |
| 2021 | 11 | 543 | 2,716 | $588,270 | $341,717 |
| 2020 | 11 | 582 | 3,192 | $623,755 | $266,106 |
Total Patients
2,790
Total Services
13,426
Medicare Billing
$1.5M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 308 | 1,887 | $330,225 | $184,675 | 55.9% |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, | Office | 2023 | 20 | 179 | $268,500 | $165,842 | 61.8% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 21 | 686 | $240,250 | $93,333 | 38.8% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 225 | 870 | $108,600 | $47,300 | 43.6% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 83 | 217 | $32,550 | $15,066 | 46.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 101 | $20,200 | $14,565 | 72.1% |
| 90834 | Psychotherapy, 45 minutes | Office | 2023 | 35 | 180 | $27,000 | $14,337 | 53.1% |
| G2082 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, incl | Office | 2023 | 15 | 16 | $16,000 | $10,446 | 65.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 122 | $18,300 | $8,409 | 46.0% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2023 | 51 | 51 | $12,750 | $7,027 | 55.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $12,950 | $5,307 | 41.0% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 40 | 41 | $8,200 | $4,479 | 54.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 26 | 26 | $9,100 | $4,107 | 45.1% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2023 | 18 | 19 | $9,350 | $3,804 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 243 | 1,646 | $288,050 | $168,968 | 58.7% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 11 | 280 | $97,825 | $38,549 | 39.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 178 | 664 | $83,000 | $38,071 | 45.9% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 59 | 153 | $22,900 | $11,157 | 48.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 50 | 50 | $17,500 | $8,992 | 51.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 55 | $8,250 | $3,916 | 47.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 16 | 86 | $11,008 | $3,682 | 33.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 16 | 86 | $11,008 | $3,416 | 31.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 17 | 17 | $5,950 | $2,757 | 46.3% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 11 | 11 | $5,500 | $2,408 | 43.8% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 12 | 12 | $3,000 | $1,704 | 56.8% |
About Dr. Ivan Cichowicz, M.D
Dr. Ivan Cichowicz, M.D is a Geriatric Psychiatry healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1932312840.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ivan Cichowicz, M.D has received a total of $169,544 in payments from pharmaceutical and medical device companies, with $31,547 received in 2024. These payments were reported across 735 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($127,740).
As a Medicare-enrolled provider, Cichowicz has provided services to 2,790 Medicare beneficiaries, totaling 13,426 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Psychiatry
- Location Boca Raton, FL
- Active Since 05/07/2007
- Last Updated 02/03/2017
- Taxonomy Code 2084P0805X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1932312840
Products in Payments
- SPRAVATO (Drug) $150,082
- VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) $6,764
- REXULTI (Drug) $3,354
- CAPLYTA (Drug) $1,462
- VRAYLAR (Drug) $1,092
- AUSTEDO (Drug) $999.66
- TRINTELLIX (Drug) $906.83
- NEUROSTAR TMS THERAPY (Device) $848.45
- BRINTELLIX (Drug) $674.34
- Auvelity (Drug) $381.48
- Austedo XR (Drug) $373.70
- ABILIFY MAINTENA (Drug) $325.38
- LYBALVI (Drug) $246.62
- NUPLAZID (Drug) $245.96
- VNS Therapy Symmetry Model 8103 Generator (Device) $215.27
- Trintellix (Drug) $168.80
- Xelstrym (Drug) $166.15
- QELBREE (Drug) $158.49
- QUVIVIQ (Drug) $156.59
- NUEDEXTA (Drug) $141.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.